All times are listed in CET (Central European Time)

Displaying One Session

View
Industry Satellite Symposium Channel 1

AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC

Date
Thu, 25.03.2021
Time
16:10 - 17:40
Room
Channel 1
Chairs
  • M. Reck (Grosshansdorf, Germany)
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

Welcome and introduction

Lecture Time
16:10 - 16:15
Speakers
  • M. Reck (Grosshansdorf, Germany)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Reck (Grosshansdorf, Germany)
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

The treatment paradigm for unresectable stage III NSCLC: Exploring the growing evidence base

Lecture Time
16:15 - 16:30
Speakers
  • M. Gottfried (Kefar Sava, Israel)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Gottfried (Kefar Sava, Israel)
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

Treating unresectable stage III NSCLC with immuno-oncology: A clinical case study

Lecture Time
16:45 - 17:00
Speakers
  • M. Reck (Grosshansdorf, Germany)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Reck (Grosshansdorf, Germany)
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

The evolving role of immuno-oncology treatment for ES-SCLC

Lecture Time
17:00 - 17:15
Speakers
  • E. Arriola (Barcelona, Spain)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • E. Arriola (Barcelona, Spain)
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

Treating 1L ES-SCLC with immuno-oncology: A clinical case study

Lecture Time
17:15 - 17:30
Speakers
  • A. Addeo (Geneva, Switzerland)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • A. Addeo (Geneva, Switzerland)
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

Live panel discussion and audience Q&A

Lecture Time
17:30 - 17:55
Speakers
  • A. Speakers (, Switzerland)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • A. Speakers (, Switzerland)